| Catalog No. | Size | Price (USD) |
| 206210-T40-50 | 50 µL | $147.96 |
| 206210-T40-100 | 100 µL | $251.64 |
| 206210-T40-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-Prostatic Acid Phosphatase/ACPP Antibody, Rabbit Polyclonal |
| Validated applications | WB (FAQ Protocol), IHC-P (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human Prostatic Acid Phosphatase/ACPP |
| Immunogen | E. coli-derived Human Prostatic Acid Phosphatase / ACPP fragment |
| Preparation | Produced in rabbits immunized with E. coli-derived Human Prostatic Acid Phosphatase / ACPP fragment, and purified by antigen affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A & Antigen Affinity |
| Formulation | PBS, pH7.0 with 0.03% Proclin300 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-ACP-3 Antibody; Anti-ACP3 Antibody; Anti-TM-PAP Antibody
Image / Experimental Information
| Image 1 Description | Anti-Prostatic Acid Phosphatase rabbit polyclonal antibody at 1:500 dilution Lane A: K562 Whole Cell Lysate Lane B: HeLa Whole Cell Lysate Lane C: HCT116 Whole Cell Lysate Lane D: Jurkat Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:45 kDa Observed band size:45 kDa (We are unsure as to the identity of these extra bands.) |
| Image 1 Alt Text | Human Prostatic Acid Phosphatase Western blot (WB) 30947 |
| Image 1 URL | Source image |
| Image 2 Description | Anti-Prostatic Acid Phosphatase rabbit polyclonal antibody at 1:500 dilution Lane A: K562 Whole Cell Lysate Lane B: HeLa Whole Cell Lysate Lane C: HCT116 Whole Cell Lysate Lane D: Jurkat Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:45 kDa Observed band size:45 kDa (We are unsure as to the identity of these extra bands.) |
| Image 2 Alt Text | Human Prostatic Acid Phosphatase Immunohistochemistry(IHC) 30948 |
| Image 2 URL | Source image |
Background Information
| Full Name | acid phosphatase, prostate |
| Description | Prostatic acid phosphatase (PAP, or ACPP), also known as prostatic specific acid phosphatase (PSAP), is an enzyme produced by the prostate. As a non-specific phosphomonoesterase, Prostatic acid phosphatase is synthesized and secreted into seminal plasma under androgenic control. The enzyme is a dimer of molecular weight around 100 kDa. Prostatic acid phosphatase is a clinically important protein for its relevance as a biomarker of prostate carcinoma. Furthermore, it has a potential role in fertilization. The major action of PAP is to dephosphorylate macromolecules with the help of catalytic residues (His(12) and Asp(258)) that are located in the cleft between two domains. Cellular prostatic acid phosphatase (cPAcP), an authentic tyrosine phosphatase, is proposed to function as a negative growth regulator of prostate cancer (PCa) cells in part through its dephosphorylation of ErbB-2. cPAcP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor receptor-2) at the phosphotyrosine (p-Tyr) residues. Injection of the secretory isoform of PAP has potent antinociceptive effects in mouse models of chronic pain. This enzyme exhibits ecto-5'-nucleotidase activity, is widely distributed, and implicated in the formation of chronic pain. Additionally, PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers. |
| Research Areas |
|
| References |
|
-HD13FE2012-WB.png){kind=link}
-HD13FE2012-5000-human-prostate-IHC-P.png){kind=link}